Erasca, Inc. Skyrocketed
Wed, Jan 07, 2026 at 07:23 PM
Erasca, Inc. (ERAS:NASDAQ) jumped higher at $5.17, representing a gain of 42.4%. On Wed, Jan 07, 2026, ERAS:NASDAQ touched a New 2-Week High of $5.17. The stock appeared on our News Catalysts scanner on Wed, Jan 07, 2026 at 04:26 PM in the 'ACQUISITION' category. From Wed, Dec 24, 2025, the stock recorded 62.50% Up Days and 66.67% Green Days
The stock spiked on Wed, Jan 07, 2026 at $6.49 with a volume of 41M+.
About Erasca, Inc. (ERAS:NASDAQ)
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Top 10 Gainers:
- SMX (Security Matters) Public Limited Company (SMX:NASDAQ), 76.14%
- Regencell Bioscience Holdings Limited (RGC:NASDAQ), 60.1%
- Nuvve Holding Corp. (NVVE:NASDAQ), 59.55%
- Innovative Eyewear, Inc. (LUCY:NASDAQ), 47.46%
- Monte Rosa Therapeutics, Inc. (GLUE:NASDAQ), 45.41%
- Century Therapeutics, Inc. (IPSC:NASDAQ), 44.44%
- NovaBay Pharmaceuticals, Inc. (NBY:NYSEMKT), 43.98%
- Erasca, Inc. (ERAS:NASDAQ), 42.42%
- Momentus Inc. (MNTS:NASDAQ), 41.4%
- Liminatus Pharma, Inc. (LIMN:NASDAQ), 41.27%